Boehringer Ingelheim v. Sun Pharmaceutical: Empagliflozin Consent Judgment
Boehringer Ingelheim secured a consent judgment against Sun Pharmaceutical and Ohm Laboratories covering 11 patents protecting JARDIANCE, GLYXAMBI, SYNJARDY XR, and TRIJARDY XR. Sun is enjoined from launching generic empagliflozin products until all asserted patents expire — a resolution reached after 1,377 days of litigation across multiple consolidated Delaware actions.
Multi-patent ANDA blockade secures Boehringer’s entire empagliflozin franchise
Boehringer Ingelheim Corporation and Boehringer Ingelheim International GmbH filed suit against Sun Pharmaceutical Industries, Inc. and Ohm Laboratories, Inc. in the District of Delaware on October 22, 2021, asserting infringement arising from Sun’s ANDA filings seeking approval to market generic versions of JARDIANCE (empagliflozin), GLYXAMBI (empagliflozin/linagliptin), SYNJARDY XR (empagliflozin/metformin ER), and TRIJARDY XR (empagliflozin/linagliptin/metformin ER). The case was one of several consolidated Delaware actions stretching back to 2018, collectively placing 11 patents at issue.
The litigation concluded on July 30, 2025, via a consent judgment entered by Judge Colm F. Connolly. Under its terms, all 11 patents — the ‘938, ‘957, ‘998, ‘637, ‘705, ‘016, ‘379, ‘172, ‘120, ‘449, and ‘323 patents — were declared valid, enforceable, and infringed by Sun’s ANDA products. Sun and its successors are permanently enjoined from making, selling, importing, or distributing the infringing products in the United States until each patent’s expiry, including any patent term extension, adjustment, or pediatric exclusivity.
The nearly four-year duration across multiple consolidated dockets suggests complex multi-product negotiations rather than a swift capitulation, consistent with Boehringer seeking to protect a franchise generating substantial revenue. The consent judgment structure — with no cost award and explicit carve-outs permitting Sun to challenge these patents against different products — suggests a negotiated resolution rather than a full trial adjudication. The specific commercial terms of any parallel settlement agreement between the parties remain undisclosed in the public record.
Filing to Consent Judgment in 1377 days
1,377 days — nearly 4 years of consolidated multi-product ANDA litigation before resolution
Consent judgment entered: what the order means for both parties
Consent judgment is a court-enforceable negotiated order
A consent judgment is a binding court order jointly agreed by the parties, carrying the same enforcement weight as a litigated verdict. Here, the court formally declares 11 patents valid, enforceable, and infringed — not as a finding after trial, but as a stipulated legal conclusion. Crucially, any future breach of the injunction can be pursued directly in the Delaware District Court, with both parties having waived venue and personal jurisdiction defenses.
Stipulated infringement findingBoehringer secures injunctive protection across its full SGLT-2 franchise
Boehringer Ingelheim obtained the broadest available relief short of a jury verdict: a permanent injunction blocking Sun from entering the market with any of the five ANDA product families until all 11 patents expire. The order also allows Boehringer to return to court if additional regulatory exclusivities are granted, future-proofing the protection. No cost award limits the financial exposure of the resolution.
Full injunction until patent expirySun retains rights to challenge patents on non-ANDA products
Sun and Ohm are barred from commercialising the five ANDA product lines in the United States for the duration of all 11 patents. However, the consent judgment explicitly preserves Sun’s right to challenge the validity, enforceability, and infringement of these patents in connection with any product not described in the five ANDAs at issue. This carve-out suggests the settlement was carefully negotiated to limit — but not entirely foreclose — Sun’s future IP positioning.
Market entry blocked; challenge rights preservedJARDIANCE franchise shielded from generic competition until patent cliff
With 11 patents upheld across four commercial products, Boehringer’s empagliflozin franchise — which includes the blockbuster JARDIANCE and its combination successors — faces no generic competition from Sun through the patent term. For the broader SGLT-2 inhibitor sector, the outcome reinforces that layered multi-patent protection strategies can effectively extend exclusivity across product families. Rival generic filers and formulation developers should note the explicit product-specific carve-out as a potential litigation pathway.
Generic entry delayed; franchise protectedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Boehringer-Ingelheim | Individual | Global pharmaceutical innovator — holder of 11 empagliflozin-related patents including US11090323B2Search in Eureka ↗ |
| Co-Plaintiff | Boehringer Ingelheim Corporation | Company | Search in Eureka ↗ |
| Co-Plaintiff | Boehringer Ingelheim International, GMBH | Company | Search in Eureka ↗ |
| Defendant | Sun Pharmaceutical Industries, Inc. | Company | Generic drug manufacturer and subsidiary Ohm Laboratories seeking ANDA approval for empagliflozin productsSearch in Eureka ↗ |
| Co-Defendant | Ohm Laboratories, Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | Sun Pharmaceutical Industries, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Brian P. Egan | Attorney | Counsel for Boehringer-IngelheimSearch in Eureka ↗ |
| Plaintiff counsel | Jack B. Blumenfeld | Attorney | Counsel for Boehringer-IngelheimSearch in Eureka ↗ |
| Plaintiff counsel | Megan Elizabeth Dellinger | Attorney | Counsel for Boehringer-IngelheimSearch in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Boehringer-IngelheimSearch in Eureka ↗ |
| Defendant counsel | Charles B. Klein | Attorney | Counsel for Sun Pharmaceutical Industries, Inc.Search in Eureka ↗ |
| Defendant counsel | David A. Bilson | Attorney | Counsel for Sun Pharmaceutical Industries, Inc.Search in Eureka ↗ |
| Defendant counsel | Jason Z. Pesick | Attorney | Counsel for Sun Pharmaceutical Industries, Inc.Search in Eureka ↗ |
| Defendant counsel | John C. Phillips , Jr. | Attorney | Counsel for Sun Pharmaceutical Industries, Inc.Search in Eureka ↗ |
| Defendant counsel | Jovial Wong | Attorney | Counsel for Sun Pharmaceutical Industries, Inc.Search in Eureka ↗ |
| Defendant law firm | Phillips, McLaughlin & Hall PA | Law Firm | Representing Sun Pharmaceutical Industries, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Colm F. Connolly | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consent judgment’s operative language — that the 11 patents ‘are valid, enforceable, and infringed’ — constitutes a stipulated court finding, not a merits adjudication after trial. This distinction matters: the patents were not tested through claim construction, expert testimony, or cross-examination. The explicit carve-out permitting Sun to challenge these same patents for different products underscores that the infringement finding is product-specific and ANDA-limited. The court’s retained jurisdiction to enforce the order and award preliminary injunctive relief for any breach gives Boehringer a swift enforcement mechanism if Sun attempts a premature launch.
US11090323B2 — Empagliflozin pharmaceutical compositions
US11090323B2, filed under application number US16/288192, is one of 11 patents asserted by Boehringer Ingelheim in this litigation, covering empagliflozin-based pharmaceutical compositions. Empagliflozin is an SGLT-2 inhibitor approved for treatment of type 2 diabetes and, subsequently, heart failure and chronic kidney disease. The ‘323 patent, like the others in the asserted portfolio, protects specific formulation and composition aspects of the empagliflozin franchise, supporting Boehringer’s JARDIANCE, GLYXAMBI, SYNJARDY XR, and TRIJARDY XR product lines.
The breadth of the 11-patent portfolio asserted in this consolidated litigation — spanning the base empagliflozin compound, fixed-dose combinations with linagliptin and metformin, and extended-release formulations — reflects a classic evergreening and layering strategy in pharmaceutical IP. For competitors developing SGLT-2 inhibitor generics or follow-on therapies, the consent judgment signals that any ANDA filer must contend with a deep, multi-layer patent estate that has now been judicially stipulated as valid and enforceable against Sun’s specific product profiles.
Should you run an FTO against US11090323B2 and the empagliflozin patent portfolio?
Any company developing generic empagliflozin tablets, empagliflozin/linagliptin combinations, or empagliflozin/metformin extended-release formulations should treat this consent judgment as a high-priority FTO trigger. The 11 patents upheld here cover a wide formulation and combination space — and while the stipulated infringement finding applies only to Sun’s five ANDAs, the underlying patent claims remain enforceable against all third parties. Formulators, CDMO partners, and generic filers outside the Sun ANDA set face the same patent landscape without the benefit of Sun’s negotiated carve-out.
PatSnap Eureka’s FTO Search Agent can map the full Boehringer Ingelheim empagliflozin patent portfolio against your specific product formulation, dosage form, and route of administration — identifying claim overlap, expiry dates including potential pediatric exclusivity extensions, and any post-grant proceedings. Eureka’s litigation overlay also flags which patents have been asserted in ANDA cases, helping your team prioritise freedom-to-operate risk before ANDA filing or product launch decisions.
Run a freedom-to-operate analysis on US11090323B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA patent cases: SGLT-2 inhibitor litigation in Delaware
Explore related ANDA infringement actions involving SGLT-2 inhibitors and empagliflozin patents litigated in the District of Delaware.
Related patent case — similar technology
Comparable case in the same technology domain. Patent holder and defendant reached resolution after proceedings.
SettledRelated infringement action — same court
Comparable GLYXAMBI® (empagliflozin/linagliptin) tablets, for oral use, in 10 mg/5 mg and 25 mg/5 mg dosages-adjacent infringement action. Patent enforcement dynamics analysed in depth.
Active · District CourtRelated invalidity challenge — appellate outcome
Combined invalidity and infringement action in the same technology space. Decided after substantive proceedings.
DecidedBoehringer-Ingelheim’s broader IP enforcement history
Boehringer-Ingelheim’s full litigation history covering prior enforcement, licensing activity, and inter partes review proceedings.
Portfolio viewWhat this case signals for the SGLT-2 inhibitor IP landscape
A multi-patent consent judgment across four empagliflozin products sets a high bar for generic entry into a blockbuster diabetes franchise.
Layered patent portfolios can block generic entry across entire drug families
Boehringer’s ability to assert 11 patents spanning the base compound, combinations, and extended-release formulations demonstrates how a coordinated ANDA litigation strategy across consolidated cases can protect an entire franchise. Generic challengers face not just one invalidity argument but a portfolio-wide defense burden.
Consent judgments without cost awards signal negotiated market-access deals
The absence of any attorneys’ fee or cost award, combined with the product-specific carve-out, is consistent with an agreed entry date tied to specific patent expirations rather than a pure litigation defeat. Pharma IP teams should read these structural signals when assessing the real competitive timeline for generic launch.
The Sun carve-out creates a future litigation vector worth monitoring
The explicit preservation of Sun’s right to challenge all 11 patents for non-ANDA products is an unusual consent judgment provision. It suggests Sun may be positioning for future product development or licensing negotiations around empagliflozin chemistry, warranting ongoing portfolio surveillance by Boehringer and other SGLT-2 stakeholders.
Pediatric exclusivity and patent term extensions could push the date further
The consent judgment expressly covers patent term extensions, patent term adjustments, and pediatric exclusivity — meaning the injunction period may extend beyond nominal patent expiry dates. Competitors and formulators tracking the actual generic entry window should model each of these regulatory extensions against each of the 11 patents independently.
Boehringer-Ingelheim v Sun — key questions answered
The consent judgment, entered July 30, 2025 in the Delaware District Court, declared 11 of Boehringer Ingelheim’s patents valid, enforceable, and infringed by Sun’s ANDA products covering empagliflozin, empagliflozin/linagliptin, and empagliflozin/metformin formulations. Sun and Ohm Laboratories are permanently enjoined from marketing those generic products in the United States until all 11 patents expire, including any term extensions or pediatric exclusivity.
The injunction covers Sun’s generic equivalents to JARDIANCE (empagliflozin), GLYXAMBI (empagliflozin/linagliptin), SYNJARDY XR (empagliflozin/metformin ER), and TRIJARDY XR (empagliflozin/linagliptin/metformin ER), as described in ANDA Nos. 212343, 212339, 214843, 215873, and 215529. Products not described in those ANDAs are explicitly excluded from the infringement finding.
Yes, with an important limitation. The consent judgment expressly preserves Sun’s right to challenge the validity, enforceability, and infringement of all 11 patents in connection with any product other than those described in the five ANDAs at issue. Sun cannot challenge those patents in relation to the enjoined ANDA products but retains broader challenge rights for future or different product profiles.
Eleven patents were asserted and upheld: the ‘938, ‘957, ‘998, ‘637, ‘705, ‘016, ‘379, ‘172, ‘120, ‘449, and ‘323 patents. The case with docket number 1:21-cv-01487 was one of several consolidated Delaware actions; earlier dockets dating to 2018 were all resolved under the same consent judgment, which dismissed all remaining claims without prejudice.
The consent judgment extends the injunction through any patent term extension, patent term adjustment, or pediatric exclusivity period applicable to the 11 patents. This means Sun’s market exclusion is not capped at the nominal patent expiry dates — it runs through any regulatory extension Boehringer obtains. The order also allows Boehringer to apply to the court to incorporate any additional regulatory exclusivities not yet identified, making the injunction dynamically expandable.
Monitor the empagliflozin patent estate before your next ANDA filing
With 11 patents upheld across four commercial products, the empagliflozin patent landscape demands continuous monitoring. Use PatSnap Eureka to run FTO searches, track patent expiry extensions, and receive alerts on new ANDA filings or IPR petitions against the Boehringer portfolio.
PatSnap Eureka searches patents and litigation data to answer instantly.